PT3094353T - Anticorpos específicos para o rsv e as suas partes funcionais - Google Patents

Anticorpos específicos para o rsv e as suas partes funcionais

Info

Publication number
PT3094353T
PT3094353T PT157370685T PT15737068T PT3094353T PT 3094353 T PT3094353 T PT 3094353T PT 157370685 T PT157370685 T PT 157370685T PT 15737068 T PT15737068 T PT 15737068T PT 3094353 T PT3094353 T PT 3094353T
Authority
PT
Portugal
Prior art keywords
rsv
specific antibodies
functional parts
functional
parts
Prior art date
Application number
PT157370685T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of PT3094353T publication Critical patent/PT3094353T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027Paramyxoviridae, e.g. respiratory syncytial virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT157370685T 2014-01-15 2015-01-14 Anticorpos específicos para o rsv e as suas partes funcionais PT3094353T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461927819P 2014-01-15 2014-01-15

Publications (1)

Publication Number Publication Date
PT3094353T true PT3094353T (pt) 2020-06-08

Family

ID=53543612

Family Applications (1)

Application Number Title Priority Date Filing Date
PT157370685T PT3094353T (pt) 2014-01-15 2015-01-14 Anticorpos específicos para o rsv e as suas partes funcionais

Country Status (26)

Country Link
US (6) US20160340414A1 (enExample)
EP (3) EP4353316A3 (enExample)
JP (4) JP6836398B2 (enExample)
KR (1) KR102188437B1 (enExample)
CN (2) CN105916520A (enExample)
AU (4) AU2015206570A1 (enExample)
CA (1) CA2933200C (enExample)
CY (2) CY1123425T1 (enExample)
DK (1) DK3094353T3 (enExample)
ES (1) ES2795727T3 (enExample)
FI (1) FIC20230016I1 (enExample)
FR (1) FR23C1016I1 (enExample)
HR (1) HRP20200607T1 (enExample)
HU (2) HUE048855T2 (enExample)
LT (2) LT3094353T (enExample)
LU (1) LUC00305I2 (enExample)
MX (1) MX374517B (enExample)
NL (1) NL301228I2 (enExample)
NO (1) NO2023016I1 (enExample)
PL (1) PL3094353T3 (enExample)
PT (1) PT3094353T (enExample)
RS (1) RS60387B1 (enExample)
SI (1) SI3094353T1 (enExample)
SM (1) SMT202000282T1 (enExample)
TW (1) TWI705974B (enExample)
WO (1) WO2015108967A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
SI3094353T1 (sl) 2014-01-15 2020-07-31 Medimmune, Llc RSY-specifična protitelesa in njihovi funkcionalni deli
US11479600B2 (en) 2016-10-21 2022-10-25 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
TW202228779A (zh) * 2017-03-01 2022-08-01 英商梅迪繆思有限公司 抗rsv單株抗體配製物
WO2019152600A1 (en) * 2018-01-31 2019-08-08 The Wistar Institute Of Anatomy And Biology Nucleic acid antibody constructs for use against respiratory syncytial virus
CN111606993B (zh) * 2019-02-26 2022-06-28 中国科学院上海生命科学研究院 抗呼吸道合胞病毒的全人广谱中和抗体4f1及其应用
US12024553B2 (en) 2019-04-30 2024-07-02 Medimmune Limited Dosage regimens for and compositions including anti-RSV antibodies
EP4402166A2 (en) 2021-09-13 2024-07-24 MedImmune Limited Prevention of respiratory syncytial virus lower respiratory tract infection with nirsevimab
CN116987183B (zh) * 2022-07-22 2024-10-15 北京智仁美博生物科技有限公司 抗呼吸道合胞病毒中和性抗体及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
JP2008518936A (ja) * 2004-10-29 2008-06-05 メディミューン,インコーポレーテッド Rsv感染症および関連状態を予防および治療する方法
AU2005335714B2 (en) * 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
SG178712A1 (en) 2006-10-02 2012-03-29 Medarex Inc Human antibodies that bind cxcr4 and uses thereof
CN101679513A (zh) 2007-03-06 2010-03-24 西福根有限公司 用于治疗呼吸道合胞病毒感染的重组抗体
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
AU2008268362A1 (en) 2007-06-26 2008-12-31 Medimmune, Llc Methods of treating RSV infections and related conditions
US8092804B2 (en) * 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
EP2240581B1 (en) 2008-01-15 2016-05-11 AbbVie Inc. Improved mammalian expression vectors and uses thereof
ES2666584T3 (es) * 2009-07-15 2018-05-07 Aimm Therapeutics B.V. Medios y métodos para producir anticuerpos de alta afinidad
CA2776249C (en) 2009-10-06 2021-01-19 Medimmune Ltd Rsv-specific binding molecule
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
US20120263715A1 (en) 2009-10-28 2012-10-18 Medimmune, Llc Topical Methods Of Treating RSV Infections And Related Conditions
EP2825191B1 (en) 2012-03-16 2019-08-28 University Health Network Soluble toso protein and its use in treating autoimmune disorders
IN2014DN09951A (enExample) * 2012-05-22 2015-08-14 Shire Human Genetic Therapies
DK2950886T3 (da) 2013-02-01 2020-03-23 Medimmune Llc Respiratorisk syncytialvirus-f-protein-epitoper
SI3094353T1 (sl) 2014-01-15 2020-07-31 Medimmune, Llc RSY-specifična protitelesa in njihovi funkcionalni deli
EP3589318A1 (en) 2017-03-01 2020-01-08 MedImmune Limited Formulations of monoclonal antibodies
TW202228779A (zh) 2017-03-01 2022-08-01 英商梅迪繆思有限公司 抗rsv單株抗體配製物

Also Published As

Publication number Publication date
AU2020203831A1 (en) 2020-07-02
LT3094353T (lt) 2020-08-10
CN116355080A (zh) 2023-06-30
CN105916520A (zh) 2016-08-31
AU2021204339B2 (en) 2024-11-14
MX374517B (es) 2025-03-06
BR112016015044A2 (pt) 2017-09-19
US20190106482A1 (en) 2019-04-11
CA2933200C (en) 2025-05-06
JP6836398B2 (ja) 2021-03-03
WO2015108967A8 (en) 2015-10-01
LTPA2023514I1 (enExample) 2023-05-25
CA2933200A1 (en) 2015-07-23
WO2015108967A2 (en) 2015-07-23
LTC3094353I2 (enExample) 2025-07-10
US11186628B2 (en) 2021-11-30
US11661449B2 (en) 2023-05-30
TW201612191A (en) 2016-04-01
AU2025201056A1 (en) 2025-03-06
HUS2300019I1 (hu) 2023-05-28
US20230365660A1 (en) 2023-11-16
MX2016008639A (es) 2017-02-15
JP2023052693A (ja) 2023-04-11
CY1123425T1 (el) 2021-12-31
SI3094353T1 (sl) 2020-07-31
RS60387B1 (sr) 2020-07-31
HUE048855T2 (hu) 2020-08-28
NL301228I1 (enExample) 2023-05-03
ES2795727T3 (es) 2020-11-24
SMT202000282T1 (it) 2020-07-08
US20250179153A1 (en) 2025-06-05
AU2021204339A1 (en) 2021-07-22
US20200331989A1 (en) 2020-10-22
FR23C1016I1 (fr) 2023-06-23
US10689437B2 (en) 2020-06-23
FIC20230016I1 (fi) 2023-04-26
EP3094353B1 (en) 2020-04-01
NO2023016I1 (no) 2023-04-25
PL3094353T3 (pl) 2020-09-07
RU2016133247A3 (enExample) 2019-01-16
EP3741390A1 (en) 2020-11-25
CY2023011I1 (el) 2023-11-15
EP3094353A4 (en) 2017-09-06
WO2015108967A3 (en) 2015-09-03
NL301228I2 (nl) 2023-09-13
EP4353316A2 (en) 2024-04-17
KR102188437B1 (ko) 2020-12-08
AU2015206570A1 (en) 2016-07-14
HRP20200607T1 (hr) 2020-07-10
CY2023011I2 (el) 2023-11-15
DK3094353T3 (da) 2020-06-02
TWI705974B (zh) 2020-10-01
JP2017504321A (ja) 2017-02-09
US20160340414A1 (en) 2016-11-24
RU2016133247A (ru) 2018-02-20
JP2025063143A (ja) 2025-04-15
HK1225992A1 (en) 2017-09-22
US20220098285A1 (en) 2022-03-31
BR112016015044A8 (pt) 2023-04-11
US12173050B2 (en) 2024-12-24
LUC00305I2 (enExample) 2025-09-22
EP3094353A2 (en) 2016-11-23
KR20160104018A (ko) 2016-09-02
EP4353316A3 (en) 2024-08-21
JP2020103293A (ja) 2020-07-09

Similar Documents

Publication Publication Date Title
IL283321A (en) Antibodies against muc16 and their uses
IL252804B (en) Anti-c10orf54 antibodies and their use
IL251248A0 (en) Anti-interleukin-33 antibodies and their uses
ZA201605894B (en) Anti-egfrviii antibodies and uses thereof
GB201403875D0 (en) Novel antibodies and uses thereof
IL254954B (en) Anti-pacap antibodies and their uses
GB201413913D0 (en) Novel antibodies and uses thereof
IL251837A0 (en) Anti-endoglin antibodies and their uses
ZA201701663B (en) Anti-il-25 antibodies and uses thereof
HUS2300019I1 (hu) RSV-re specifikus ellenanyagok és azok funkcionális részei
IL247315A0 (en) Anti-acth antibodies and their uses
IL282201B (en) Anti-tensin c antibodies and their uses
IL247590A0 (en) Bispecific antibodies and their uses
GB201503387D0 (en) Anti-carbapenem antibodies and uses thereof